X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (29) 29
index medicus (28) 28
humans (25) 25
cancer (16) 16
chemotherapy (13) 13
female (12) 12
survival (9) 9
aged (8) 8
breast cancer (8) 8
metastasis (8) 8
middle aged (8) 8
prognosis (8) 8
therapy (8) 8
care and treatment (7) 7
clinical trials (7) 7
patients (7) 7
adult (6) 6
antineoplastic agents - therapeutic use (6) 6
colorectal cancer (6) 6
colorectal neoplasms - drug therapy (6) 6
male (6) 6
studies (6) 6
trastuzumab (6) 6
breast neoplasms - drug therapy (5) 5
cell lung-cancer (5) 5
hematology (5) 5
hematology, oncology and palliative medicine (5) 5
immunotherapy (5) 5
metastases (5) 5
neoplasm metastasis (5) 5
antineoplastic agents - adverse effects (4) 4
capecitabine (4) 4
colorectal neoplasms - pathology (4) 4
erbb-2 protein (4) 4
gemcitabine (4) 4
immune checkpoint inhibitors (4) 4
irinotecan (4) 4
medical prognosis (4) 4
neoplasms - drug therapy (4) 4
oxaliplatin (4) 4
pancreatic cancer (4) 4
respiratory system (4) 4
review (4) 4
treatment outcome (4) 4
women (4) 4
1st-line treatment (3) 3
adjuvant treatment (3) 3
age (3) 3
age factors (3) 3
aged, 80 and over (3) 3
analysis (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
breast neoplasms - pathology (3) 3
cancer therapies (3) 3
cardiovascular disease (3) 3
docetaxel (3) 3
drug therapy (3) 3
elderly-patients (3) 3
gastroenterology and hepatology (3) 3
lung neoplasms - pathology (3) 3
management (3) 3
medicine (3) 3
medicine & public health (3) 3
melanoma (3) 3
multidisciplinary sciences (3) 3
mutation (3) 3
neoplasms (3) 3
open-label (3) 3
phase-iii trial (3) 3
randomized controlled trials as topic (3) 3
research (3) 3
retrospective studies (3) 3
risk factors (3) 3
science (3) 3
settore med/06 - oncologia medica (3) 3
stereotactic radiosurgery (3) 3
tumors (3) 3
tyrosine kinase inhibitors (3) 3
5-fluorouracil (2) 2
adenocarcinoma (2) 2
adverse events (2) 2
anastrozole (2) 2
anthracyclines (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
aromatase inhibitors - adverse effects (2) 2
bevacizumab (2) 2
braf (2) 2
brain metastases (2) 2
brain neoplasms - diagnostic imaging (2) 2
brain neoplasms - secondary (2) 2
breast neoplasms - diagnosis (2) 2
breast neoplasms - mortality (2) 2
breast neoplasms - surgery (2) 2
breast neoplasms - therapy (2) 2
breast-cancer (2) 2
cancer research (2) 2
capecitabine - administration & dosage (2) 2
carcinoma (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Supportive Care in Cancer, ISSN 0941-4355, 3/2019, Volume 27, Issue 3, pp. 1041 - 1047
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 08/2017, Volume 81, p. 174
Oxaliplatin (OXA)- and irinotecan (IRI)-based chemotherapies are the most frequently used salvage regimens in patients with metastatic pancreatic cancer (PC)... 
Gemcitabine | Clinical trials | Metastasis | Statistical tests | Disease control | Patients | Survival | Metastases | Studies | Irinotecan | Chemotherapy | Salvage | Oxaliplatin | Pancreatic cancer | Cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 08/2017, Volume 81, p. 174
Abstract Background: oxaliplatin (OXA)- and irinotecan (IRI)-based chemotherapies are the most frequently used salvage regimens in patients with metastatic... 
Gemcitabine | Clinical trials | Statistical tests | Disease control | Patients | Survival | Metastases | Studies | Irinotecan | Chemotherapy | Salvage | Oxaliplatin | Pancreatic cancer | Response rates | Cancer
Journal Article
Journal Article
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2016, Volume 11, Issue 5, p. e0156221
Journal Article
Clinical Nuclear Medicine, ISSN 0363-9762, 07/2016, Volume 41, Issue 7, pp. 564 - 565
ABSTRACTF-NaF is a radiopharmaceutical widely used in PET imaging to detect bone metastases. Several cases of F-NaF uptake from brain metastases have been... 
F-NaF | Brain metastasis | PET | Brain Neoplasms - secondary | Sodium Fluoride | Brain Neoplasms - diagnostic imaging | Humans | Multimodal Imaging - methods | Adult | Fluorodeoxyglucose F18 | Lung Neoplasms - pathology | Male | Radiopharmaceuticals | Positron Emission Tomography Computed Tomography - methods
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 08/2018, Volume 13, Issue 8, pp. 1113 - 1120
Determination of programmed death ligand 1 (PD-L1) expression defines eligibility for treatment with pembrolizumab in patients with advanced NSCLC. This study... 
PD-L1 | Heterogeneity | Biopsies | Lung | Cancer | RESECTED SPECIMENS | SAFETY | ANTIBODY | DEATH | RELIABILITY | PEMBROLIZUMAB | ONCOLOGY | IMMUNOTHERAPY | RESPIRATORY SYSTEM | NIVOLUMAB
Journal Article
TRANSLATIONAL LUNG CANCER RESEARCH, ISSN 2218-6751, 12/2018, Volume 7, Issue S4, pp. S341 - S345
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2015, Volume 10, Issue 9, p. e0136731
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 8, pp. 13611 - 13619
Journal Article
Journal Article